• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

Introduction to 2-Methyl-4-(pyrrolidin-1-yl) benzoic acid (CAS No. 530092-32-1)

2-Methyl-4-(pyrrolidin-1-yl) benzoic acid, identified by its Chemical Abstracts Service (CAS) number 530092-32-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the class of benzoic acid derivatives, characterized by its structural incorporation of a methyl group at the 2-position and a pyrrolidin-1-yl moiety at the 4-position. The unique combination of these functional groups imparts distinct chemical properties and biological activities, making it a subject of considerable interest for researchers exploring novel therapeutic agents.

The molecular structure of 2-Methyl-4-(pyrrolidin-1-yl) benzoic acid consists of a benzene ring substituted with a methyl group at the 2-position and an N-substituted pyrrolidine ring attached to the 4-position. This configuration creates a molecule with potential for diverse interactions with biological targets, including enzymes and receptors. The presence of the pyrrolidin-1-yl group, in particular, is noteworthy as it is frequently employed in medicinal chemistry to enhance solubility, improve pharmacokinetic profiles, and modulate binding affinities.

In recent years, there has been growing interest in exploring the pharmacological potential of benzoic acid derivatives. These compounds have shown promise in various therapeutic areas, including anti-inflammatory, analgesic, and anticancer applications. The structural features of 2-Methyl-4-(pyrrolidin-1-yl) benzoic acid suggest that it may exhibit similar properties, although further research is required to fully elucidate its biological activity.

One of the most compelling aspects of this compound is its potential as a lead molecule for drug discovery. The pyrrolidinyl moiety can serve as a hinge-binding motif, allowing the compound to interact with specific protein targets. This feature has been exploited in the development of kinase inhibitors, which are critical in treating cancers and inflammatory diseases. Additionally, the benzoic acid core is known to possess antioxidant and anti-inflammatory properties, further enhancing the therapeutic potential of 2-Methyl-4-(pyrrolidin-1-yl) benzoic acid.

Recent studies have begun to explore the interactions between benzoic acid derivatives and various biological pathways. For instance, research has indicated that certain benzoic acid analogs can modulate the activity of cyclooxygenase (COX) enzymes, which are key players in inflammation. While 2-Methyl-4-(pyrrolidin-1-yl) benzoic acid has not yet been directly studied for COX inhibition, its structural similarity suggests that it may share this property. Further investigation could reveal novel mechanisms of action and expand its therapeutic applications.

The synthesis of 2-Methyl-4-(pyrrolidin-1-yl) benzoic acid presents an interesting challenge for organic chemists due to its complex structure. Traditional synthetic routes involve multi-step reactions, including functional group transformations and protecting group strategies. However, advances in synthetic methodology have made it possible to streamline these processes, making large-scale production more feasible. Techniques such as palladium-catalyzed cross-coupling reactions have been particularly useful in constructing the pyrrolidinyl moiety efficiently.

The pharmacokinetic profile of 2-Methyl-4-(pyrrolidin-1-yl) benzoic acid is another area of active investigation. Understanding how a compound is absorbed, distributed, metabolized, and excreted (ADME) is crucial for determining its clinical efficacy and safety. Preliminary studies suggest that the pyrrolidinyl group may enhance oral bioavailability by improving solubility and permeability across biological membranes. Additionally, metabolic studies indicate that the compound undergoes biotransformation via standard pathways involving cytochrome P450 enzymes.

In conclusion,2-Methyl-4-(pyrrolidin-1-yl) benzoic acid (CAS No. 530092-32-1) represents a promising candidate for further pharmacological exploration. Its unique structural features offer potential for diverse biological activities, particularly in the realms of anti-inflammatory and anticancer therapies. As research continues to uncover new therapeutic targets and synthetic methodologies,2-Methyl-4-(pyrrolidin-1-yllbenzoicacid is poised to play an important role in the development of next-generation pharmaceuticals.

• 22090-27-3(4-(Pyrrolidin-1-yl)benzoic acid)
• 72548-79-9(3-(Pyrrolidin-1-yl)benzoic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)